You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AMD, ranibizumab

Showing 1 - 25 of 1,181
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Retinal Revascularization and Clinical Indicators of Neovascular

Recruiting
  • Wet Macular Degeneration
  • Ophthalmic Drugs
  • Arendal, Agder, Norway
    Sorlandet Hospital HF
Mar 3, 2022

Macular Degeneration Trial (Zimura, Avastin, Lucentis)

Completed
  • Macular Degeneration
  • (no location specified)
Oct 4, 2022

Wet Age-related Macular Degeneration Trial in Boston, Worcester (Intravitreal anti-VEGF, Intravitreal AAVCAGsCD59, Oral

Completed
  • Wet Age-related Macular Degeneration
  • Intravitreal anti-VEGF
  • +2 more
  • Boston, Massachusetts
  • +1 more
May 24, 2022

Reading Speed Improvements in Wet-AMD Patients After Ranibizumab

Completed
  • Ophthalmopathy
  • Wet Macular Degeneration
    • (no location specified)
    Jul 20, 2021

    Wet Age-related Macular Degeneration Trial in Beijing, Wuhan, Shanghai (CMAB818, Lucentis®)

    Recruiting
    • Wet Age-related Macular Degeneration
    • Beijing, Beijing, China
    • +3 more
    Jun 14, 2022

    Ocular Adverse Events in Neovascular Agerelated Macular

    Completed
    • Age-related Macular Degeneration (AMD)
    • Aflibercept
    • +2 more
    • East Hanover, New Jersey
      Novartis Investigative Site
    Dec 15, 2021

    Ocular Adverse Events in Neovascular Age-related Macular

    Completed
    • Age-related Macular Degeneration (AMD)
    • Aflibercept
    • +2 more
    • East Hanover, New Jersey
      Novartis Investigative Site
    Dec 15, 2021

    Neovascular (Wet) Age-related Macular Degeneration (AMD) Trial in United Kingdom (Stereotactic radiotherapy (16 Gray or Sham),

    Active, not recruiting
    • Neovascular (Wet) Age-related Macular Degeneration (AMD)
    • Stereotactic radiotherapy (16 Gray or Sham)
    • 0.5 mg ranibizumab
    • Huntingdon, Cambridgeshire, United Kingdom
    • +29 more
    Apr 1, 2022

    Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration Trial in Australia

    Completed
    • Age-related Macular Degeneration
    • +2 more
    • bevacizumab
    • ranibizumab
    • Hurstville, New South Wales, Australia
    • +8 more
    May 7, 2021

    Age-related Macular Degeneration (AMD) Trial in Worldwide (ranibizumab)

    Completed
    Has Results
    • Age-related Macular Degeneration (AMD)
    • ranibizumab
    • Vienna, Austria
    • +57 more
    Sep 2, 2021

    Following Intensive Anti-VEGF Therapy in Wet AMD

    Completed
    • Age-Related Macular Degeneration
    • Budapest, Hungary
    • +1 more
    Dec 28, 2022

    Wet Macular Degeneration, Wet Age-related Macular Degeneration Trial in Virginia Beach (Ziv-Aflibercept 25 MG/ML [Zaltrap],

    Completed
    • Wet Macular Degeneration
    • Wet Age-related Macular Degeneration
    • Virginia Beach, Virginia
      Wagner Macula & Retina Center
    Oct 5, 2020

    Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration Trial in United States

    Completed
    • Age-related Macular Degeneration
    • +2 more
    • bevacizumab
    • ranibizumab
    • Tucson, Arizona
    • +49 more
    Feb 15, 2022

    Age Related Macular Degeneration Trial in China (HLX04-O,recombinant anti-vascular endothelial growth factor (VEGF) humanized

    Recruiting
    • Age Related Macular Degeneration
    • HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection
    • Lucentis
    • Bengbu, Anhui, China
    • +40 more
    Apr 27, 2022

    Neovascular Age-Related Macular Degeneration Trial in Worldwide (Ranibizumab, Aflibercept, Port Delivery System with ranibizumab

    Suspended
    • Neovascular Age-Related Macular Degeneration
    • Capital Federal, Argentina
    • +9 more
    Nov 8, 2022

    Neovascular Age-related Macular Degeneration Trial in Worldwide (OPT-302, ranibizumab, sham intravitreal injection)

    Completed
    • Neovascular Age-related Macular Degeneration
    • OPT-302
    • +2 more
    • Phoenix, Arizona
    • +107 more
    Jan 8, 2021

    Neovascular Age-related Macular Degeneration Trial in India (Lucentis (ranibizumab), LUBT010 (proposed ranibizumab biosimilar))

    Recruiting
    • Neovascular Age-related Macular Degeneration
    • Lucentis (ranibizumab)
    • LUBT010 (proposed ranibizumab biosimilar)
    • Guwahati, Assam, India
    • +25 more
    Mar 3, 2021

    Age-Related Macular Degeneration Trial in Hong Kong (Brolucizumab, Aflibercept)

    Recruiting
    • Age-Related Macular Degeneration
    • Hong Kong, Hong Kong
      Grantham Hospital
    Jan 25, 2023

    Age-Related Macular Degeneration Trial in Worldwide (SB11 (Proposed ranibizumab biosimilar), Lucentis (ranibizumab))

    Completed
    Has Results
    • Age-Related Macular Degeneration
    • SB11 (Proposed ranibizumab biosimilar)
    • Lucentis (ranibizumab)
    • Poway, California
    • +74 more
    Apr 29, 2021

    naïve Age-related Macular Degeneration Neovascular Type and

    Completed
    • Macular Degeneration
    • Data extraction from medical files
    • Brussels, Belgium
      CHU Brugmann
    Mar 7, 2022

    Neovascular Age-Related Macular Degeneration (nAMD) Trial in United States (RGX-314 Dose 1, RGX-314 Dose 2, Ranibizumab

    Recruiting
    • Neovascular Age-Related Macular Degeneration (nAMD)
    • RGX-314 Dose 1
    • +3 more
    • Phoenix, Arizona
    • +14 more
    Mar 29, 2022

    Exudative Macular Degeneration, Retinal Hemorrhage Trial in United Kingdom (Ranibizumab, C3F8 Gas, tPA)

    Completed
    • Exudative Macular Degeneration
    • Retinal Hemorrhage
    • Maidstone, Kent, United Kingdom
    • +4 more
    Jul 10, 2020

    Exudative Age-related Macular Degeneration Trial (intravitreal injection)

    Completed
    • Exudative Age-related Macular Degeneration
    • intravitreal injection
    • (no location specified)
    Apr 19, 2022

    Macular Degeneration, Wet, Metamorphopsia Trial

    Recruiting
    • Macular Degeneration, Wet
    • Metamorphopsia
      • Cuneo, Piedmont, Italy
        Ospedale Santa Croce
      Sep 20, 2022

      AMD, nAMD, Wet Age-related Macular Degeneration Trial in United States (RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (EYLEA®))

      Recruiting
      • AMD
      • +5 more
      • RGX-314 Dose 1
      • +2 more
      • Encino, California
      • +16 more
      Jun 2, 2022